Abstract
Respiratory virus infections precipitate asthma and chronic obstructive pulmonary disease (COPD) exacerbations, with most exacerbations due to rhinovirus infection. Both asthma andCOPDexacerbations are not well controlled by steroid therapies, and there is a much research interest in finding improved therapies or combinations of therapies for controlling exacerbations.CHF6001 is a new, inhaled highly potent and selective phosphodiesterase type 4 (PDE4) inhibitor. Using in vitro human bronchial epithelial cells (BEAS‐2B), we investigated the potential anti‐inflammatory effects ofCHF6001 on rhinovirus (RV1B)‐induced cytokines. CytokinemRNAwas measured by real‐timePCR, while protein release was measured byELISA.CHF6001 was used in a 7‐point dose–response curve (1000–0.001 nmol/L) as a 1.5‐h pretreatment prior to infection in comparison with roflumilast. Both roflumilast andCHF6001 reducedRV1B‐inducedIL‐8,IL‐29,IP‐10, and RANTES mRNA and protein in a concentration‐dependent manner. Generally,CHF6001 was 13‐ to 16‐fold more potent (subnanomolarEC50values) than roflumilast at reducingIL‐8,IL‐29,IP‐10, andRANTES mRNAand protein release, but had similar efficacies. In combination with the steroid fluticasone propionate (1 nmol/L),CHF6001 had additive effects, significantly reducingRV‐induced cytokines when compared with steroid orCHF6001 alone. Combined low‐dose steroid and low‐doseCHF6001 had a similar efficacy as high‐dose steroid orCHF6001 alone, indicating the combination had steroid andPDE4 inhibitor sparing effects. Overall results indicate thatPDE4 inhibitors have anti‐inflammatory activity against virus‐induced inflammatory mediators and thatCHF6001 is more potent than roflumilast.
Funding Information
  • Chiesi Farmaceutici

This publication has 63 references indexed in Scilit: